New clients start with a short, paid Diagnostic Advisory Engagement. In that engagement I assess your growth performance and your regulatory position together, because in an FDA-regulated business they are one system. Ignoring one lane is why investors walk, approvals stall, and growth plans die.
We set the objective, the constraints, and what a useful answer looks like for you.
I go through what the business actually shows rather than what the deck says.
We test the findings against your reality and pressure the options together.
The written diagnosis lands, and we walk it end to end.
The Diagnostic Advisory Engagement ends with a written strategy report and a live strategy session. The report gives you a clear picture of your growth performance and your regulatory position, and of how each one is constraining the other. The session turns that picture into concrete decisions and next steps.
A written diagnosis of the core issues, the key risks, and a small set of practical options. Plus a live strategy session to work through it.
The document is something you can take to your board and your counsel. The session is where we say the hard things out loud.
After the diagnostic, we either move into focused work on growth or on regulatory strategy, or you take the findings and act on them with your own team. The diagnostic stands on its own. It is not a sales call with a fee attached.
I work with teams who are ready to pay for a clear, honest diagnosis before committing to larger work. If you are looking for free motivation or generic advice, I am not the right fit.
Because growth, regulatory, and capital decisions are tied together, and you deserve a clear diagnosis before anyone sells you a big project. This engagement gives us both the information we need to decide what work, if any, makes sense next.
A brief qualifying exchange comes first, so we both know the diagnostic is the right use of your money. The fee is set out in the proposal.
Inquire about a diagnostic